AVTX-009 / Avalo Therap, Eli Lilly - LARVOL DELTA

Avalo Reports 2024 Financial Results and Recent Business Updates (GlobeNewswire) - "Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026."

P2 data • Hidradenitis Suppurativa

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa (GlobeNewswire) - "Avalo Therapeutics...announced that the first patient has been dosed in the Company’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS)....The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults with moderate to severe hidradenitis suppurativa."

Trial status • Hidradenitis Suppurativa

LOTUS: A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Avalo Therapeutics, Inc.

New P2 trial • Dermatology • Hidradenitis Suppurativa • Immunology

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa (GlobeNewswire) - "Avalo Therapeutics...announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year....The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults with moderate to severe HS. The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16."

IND • New P2 trial • Hidradenitis Suppurativa

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire) - "Avalo Therapeutics...announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc....The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million....Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS). Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027. In addition to HS, Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication."

M&A • New P2 trial • Hidradenitis Suppurativa • Inflammation